Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -2763.64% is 75% above its 5-year average of -11171.38%, near the low end of its 5-year range (-82777.31%–8349500.00%).
63.19% above its 12-month average of -7507.72%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -23916.29%.
NET PROFIT MARGIN
-2763.64%
NET PROFIT MARGIN AVG TTM
-7507.72%
NET PROFIT MARGIN AVG 3Y
-589.43%
NET PROFIT MARGIN AVG 5Y
-11171.38%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+63.19%
CURRENT VS 3Y AVG
-368.87%
CURRENT VS 5Y AVG
+75.26%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-1062838.46%
vs the sector median at left
Relay Therapeutics, Inc.
Market Cap
$4.03B
Net Profit Margin
-2763.64%
TTM Avg
-7507.72%
3Y Avg
-589.43%
5Y Avg
-11171.38%
Market Cap
$4.07B
Net Profit Margin
-248.83%
TTM Avg
-379.86%
3Y Avg
-278.01%
5Y Avg
-170.03%
Market Cap
$3.95B
Net Profit Margin
1.39%
TTM Avg
-2.46%
3Y Avg
-2.37%
5Y Avg
0.86%
Market Cap
$4.13B
Net Profit Margin
12.82%
TTM Avg
-6.21%
3Y Avg
-4.84%
5Y Avg
-11.63%
Market Cap
$3.88B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.29B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.39B
Net Profit Margin
-20.73%
TTM Avg
-55.30%
3Y Avg
-87.73%
5Y Avg
-105.64%
Market Cap
$4.42B
Net Profit Margin
-55.82%
TTM Avg
-71.50%
3Y Avg
-84.24%
5Y Avg
-84.24%
Market Cap
$4.43B
Net Profit Margin
26.65%
TTM Avg
8.56%
3Y Avg
0.11%
5Y Avg
0.58%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Relay Therapeutics, Inc. (RLAY) | $4.03B | -2763.64% | -7507.72% | -589.43% | -11171.38% |
| AbCellera Biologics Inc. (ABCL)vs › | $4.07B | -248.83% | -379.86% | -278.01% | -170.03% |
| ICU Medical, Inc. (ICUI)vs › | $3.95B | 1.39% | -2.46% | -2.37% | 0.86% |
| LivaNova PLC (LIVN)vs › | $4.13B | 12.82% | -6.21% | -4.84% | -11.63% |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.88B | 0.00% | 0.00% | 0.00% | 0.00% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.29B | 0.00% | 0.00% | 0.00% | 0.00% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.39B | -20.73% | -55.30% | -87.73% | -105.64% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.42B | -55.82% | -71.50% | -84.24% | -84.24% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.43B | 26.65% | 8.56% | 0.11% | 0.58% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.55B | -1.69% | -12.55% | -19.61% | -21.06% |
Operating Margin
-1971.6%
Net Profit Margin
-2763.6%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -23916.29% |
| 2026-03-31 | -2443.03% |
| 2025-12-31 | -784.14% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | -10395.13% |
| 2025-03-31 | -1003.58% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | -813.30% |
| 2023-12-31 | 8349500.00% |
| 2023-09-30 | -260.83% |
| 2023-06-30 | -82777.31% |
| 2023-03-31 | -41698.67% |
| 2022-12-31 | -26681.03% |
| 2022-09-30 | -24468.60% |
| 2022-06-30 | -21037.81% |
| 2022-03-31 | -14808.11% |
| 2021-12-31 | -11897.00% |
| 2021-09-30 | -9134.08% |
| 2021-06-30 | -22914.57% |
| 2021-03-31 | -4431.09% |
| 2020-12-31 | 42.68% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
